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Abstract
Introduction The importance of the tumor microenvironment in
breast cancer has been increasingly recognized. Critical
molecular changes in the tumor stroma accompanying cancer
progression, however, remain largely unknown. We conducted
a comparative analysis of global gene expression changes in the
stromal and epithelial compartments during breast cancer
progression from normal to preinvasive to invasive ductal
carcinoma.
Methods We combined laser capture microdissection and
gene expression microarrays to analyze 14 patient-matched
normal epithelium, normal stroma, tumor epithelium and tumor-
associated stroma specimens. Differential gene expression and
gene ontology analyses were performed.
Results Tumor-associated stroma undergoes extensive gene
expression changes during cancer progression, to a similar
extent as that seen in the malignant epithelium. Highly
upregulated genes in the tumor-associated stroma include
constituents of the extracellular matrix and matrix
metalloproteases, and cell-cycle-related genes. Decreased
expression of cytoplasmic ribosomal proteins and increased
expression of mitochondrial ribosomal proteins were observed
in both the tumor epithelium and the stroma. The transition from
preinvasive to invasive growth was accompanied by increased
expression of several matrix metalloproteases (MMP2, MMP11
and MMP14). Furthermore, as observed in malignant epithelium,
a gene expression signature of histological tumor grade also
exists in the stroma, with high-grade tumors associated with
increased expression of genes involved in immune response.
Conclusions Our results suggest that the tumor
microenvironment participates in tumorigenesis even before
tumor cells invade into stroma, and that it may play important
roles in the transition from preinvasive to invasive growth. The
immune cells in the tumor stroma may be exploited by the
malignant epithelial cells in high-grade tumors for aggressive
invasive growth.
Introduction
The tumor microenvironment or the stroma hosting the malig-
nant breast epithelial cells is comprised of multiple cell types,
including fibroblasts, myoepithelial cells, endothelial cells and
various immune cells [1-4]. One prevailing view is that tumor-
associated stroma is activated by the malignant epithelial cells
to foster tumor growth – for example, by secreting growth fac-
tors, increasing angiogenesis, and facilitating cell migration,
ultimately resulting in metastasis to remote organ sites [3]. For
example, two chemokines (chemokine (C-X-C motif) ligand
(CXCL) 12 and CXCL14) that bind to tumor epithelial cells to
promote proliferation, migration and invasion have recently
been shown to be overexpressed by the activated tumor
fibroblasts and myoepithelial cells [5-7]. Genes involved in
tumor-microenvironment interactions may therefore provide
novel targets for diagnostic development and therapeutic
intervention. Our understanding of the interactions between
epithelial and stromal components of breast cancer, however,
remains limited at the molecular level. Using the serial analysis
of gene expression technique, Allinen and coworkers per-
formed the first systematic profiling of the various stromal cell
types isolated via cell-type-specific cell surface markers and
magnetic beads [7]. They demonstrated gene expression
alterations in all cell types within the tumor microenvironment
CXCL: chemokine (C-X-C motif) ligand; DCIS: ductal carcinoma in situ; DCIS-S: DCIS-associated stroma; GREM1: gremlin 1; IDC: invasive ductal 
carcinoma; IDC-S: IDC-associated stroma; INHBA: inhibin beta A; LCM: laser capture microdissection; PCR: polymerase chain reaction; SFRP1: 
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accompanying progression from normal breast tissue to ductal
carcinoma in situ (DCIS) to invasive ducal carcinoma (IDC)
[8], providing evidence that these cell types all participate in
tumorigenesis.
Using laser capture microdissection (LCM), we previously per-
formed gene expression analysis of the epithelial compartment
of the malignant lesions during breast cancer progression. We
discovered that most of the gene expression changes take
place prior to local invasion (even in atypical ductal hyperpla-
sia) and that there are no major changes in gene expression
accompanying the in situ to invasive growth transition [9]. In
the present article we extend this analysis to the tumor stromal
microenvironment and demonstrate that, like the tumor epithe-
lium, the tumor stromal microenvironment undergoes extensive
gene expression alterations even at the preinvasive stage of
DCIS, supporting the view that cell-cell communication via
paracrine mechanisms between the two compartments plays
an important role in tumor progression.
Materials and methods
Clinical specimen
All breast cancer specimens were fresh-frozen biopsies
obtained from the Massachusetts General Hospital between
1998 and 2001. The diagnostic criteria and tumor grading
were described previously [9]. Patient and tumor characteris-
tics of the 14 tumor specimens in this study are presented in
Table 1. Patients were selected in which patient-matched nor-
mal and tumor samples were available and the normal breast
lobules did not show fibrocystic change. The research was
deemed exempt from informed consent as the samples are
unidentifiable to the research team. The study was approved
by the Massachusetts General Hospital human research com-
mittee in accordance with National Institutes of Health human
research study guidelines.
Laser capture microdissection, RNA extraction and 
microarray analysis
Highly enriched populations of patient-matched normal or
malignant epithelial cells and of normal stroma or tumor-asso-
ciated stroma from the different stages of breast cancer pro-
gression were procured by LCM using a PixCell IIe system
(Molecular Devices, Mountain View, CA, USA) as previously
described [9]. Enrichment for cells of interest was verified by
microscopic examination of the LCM cap after microdissec-
tion. The microdissected normal stromal compartment con-
sisted of the intralobular, rather than the extralobular, stromal
compartment of normal breast tissue that was a minimum 0.3
cm from any premalignant or malignant lesion (Figure 1). The
DCIS-associated stroma (DCIS-S) consisted of a 25 μm rim
of cells that surrounded the DCIS; for cases in which synchro-
nous DCIS and IDC were present, the DCIS-S was obtained
from areas of DCIS that were at least 0.3 cm from the invasive
component. The IDC-associated stroma (IDC-S) consists of
stromal cells predominantly within the invasive tumor mass.
Total RNA was isolated from captured cells using the Picop-
ure™ RNA isolation kit (Molecular Devices), amplified by T7
RNA amplification (RiboAmp™; Molecular Devices), labeled
and hybridized to the whole genome array U133X3P (3'-
Table 1
Patient and tumor characteristics of samples in the study
Patient number Age (years) Grade Estrogen receptor Progesterone receptor Her-2 Size Nodal status Tumor type
44 28 III Positive Positive Negative 1 Negative Ductal
45 36 I Positive Positive Negative N/A Negative Ductal
79 54 I Positive Positive Negative 2.1 Positive Ductal
96 31 III Negative Negative Negative 3.7 Negative Ductal
102 55 I Positive Negative Negative 5.2 Positive Ductal
121 45 II Positive Positive Positive 1.5 Positive Ductal
131 37 II Positive Positive Positive 1.5 Positive Ductal
133 44 III Negative Negative Positive 1.5 Positive Ductal
148 42 II Positive Positive Negative 1.9 Positive Ductal
153 46 I Positive Positive ND N/A Positive Ductal
169 34 II Positive Positive Negative 2.6 Positive Ductal
178 43 III Positive Positive Positive 2.8 Positive Ductal
179 37 III Negative Negative Positive 1.5 Positive Ductal
180 46 I Positive Positive Negative 1.9 Positive Ductal
ND, not determined; N/A, not available.Available online http://breast-cancer-research.com/content/11/1/R7
Page 3 of 18
(page number not for citation purposes)
biased design) according to the manufacturer's instructions
(Affymetrix, Santa Clara, CA, USA). The hybridized microar-
rays were then washed, stained and scanned as per the man-
ufacturer's protocols (Affymetrix).
Data analysis
Raw data from the U133X3P arrays were processed using the
Bioconductor rma package with default parameters for back-
ground correction, quantile normalization and signal summa-
tion [10,11]. Differential gene expression analyses were
performed using linear regression models in the limma pack-
age [12]. For comparing normal and tumor samples, we used
the patient identification as a blocking variable. For tumor
grade comparison, we used the tumor stage (in situ or inva-
sive) as the blocking variable. Statistical significance was cor-
rected for multiple testing using the Benjamini-Hochberg
procedure [13]. All procedures were performed in the R statis-
tical environment [14]. For gene ontology analysis, ranked
gene lists were first generated according to the moderated t
statistics from linear models and then examined for enriched
ontology terms using the Gene Set Enrichment Analysis soft-
ware [15]. The data discussed in this publication have been
deposited in the NCBI Gene Expression Omnibus [16] and
are accessible [GEO:GSE14548] [17].
Quantitative real-time PCR and immunohistochemistry
TaqMan™ real-time PCR was performed on amplified RNA
used for microarray analysis as previously described [9].
Briefly, amplified RNA was converted to double-stranded
cDNA, and the cDNA was quantitated with PicoGreen (Molec-
ular Probes, Eugene, OR, USA) using a spectrofluorometer
(Molecular Devices). Each gene was analyzed in triplicate in a
96-well plate using ABI 7900 HT (Applied Biosystems, Foster
City, CA., USA).
For each gene, the sequences of the PCR primer pairs and the
fluorogenic MGB or TAMRA probe (5' to 3'), respectively, are as
follows: ESR1, ATGATCAACTGGGCGAAGA, GGTGGACCT-
GATCATGGA and VIC-TGCCAGGCTTTGTGGA; RRM2,
CCTTTAACCAGCACAGCCAGTT, TTATTTGTTTGTAAAGT-
GCCAGGTTT and VIC-TGCAGCCTCACTGCTTCAACGCA-
TAMRA; gremlin 1 (GREM1), ACGGCAAAGAATTATATAGAC-
TATGAGGTA, TTTTATGAGACTATCAACTCCCCTTTC and
VIC-CTTGCTGTGTAGGAGGA; and WNT inhibitory factor
1(WIF1), CACTGTGGTAGTGGCATTTAAACAATA, GCCAAT-
GCAAAAAGTTCATACATT and VIC-TTCTAAACACAAT-
GAAATAGGGA.
Estrogen receptor and progesterone receptor immunohisto-
chemistry staining was performed as previously described,
using the rabbit monoclonal antibody (SP1) from Lab Vision
(Fremont, CA, USA) for the estrogen receptor (1:50 dilution)
and using the mouse monoclonal antibody (PgR 636) from
Dako (Carpinteria, CA, USA) for the progesterone receptor
(1:50 dilution) [18].
Results
Experimental design
The present study included 14 patients with primary ductal
breast cancer (Table 1). These patients were primarily estro-
gen receptor positive (78.6%), lymph node positive (78.6%),
and premenopausal (mean age 41 years). We used LCM to
isolate the epithelial and stroma compartments separately
from each of the 14 fresh-frozen biopsies. In the epithelial
compartment, we captured normal and malignant epithelium
from DCIS and/or IDC. In the stromal compartment, we cap-
tured normal stroma at least 3 mm from the malignant lesion
and the DCIS-S and/or IDC-S whenever possible. An example
of the microdissected compartments is shown in Figure 1. As
Figure 1
Laser capture microdissection experimental design Laser capture microdissection experimental design. Example of the 
tumor microenvironment compartments targeted by laser capture 
microdissection: epithelial (white asterisk) and stromal (black outlined 
areas with black asterisk) compartments of the normal terminal ductal 
lobular unit, of ductal carcinoma in situ (DCIS) and of invasive ductal 
carcinoma (IDC).Breast Cancer Research    Vol 11 No 1    Ma et al.
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shown in Table 2, in the epithelial compartment four cases had
all three stages (normal breast epithelium, DCIS, and IDC)
available, five cases had normal breast epithelium and IDC
only, and five cases had normal breast epithelium and DCIS
only; in the stroma, six cases had all three stages available, five
cases had normal stromal compartment and DCIS-S, and
three cases had the normal stromal compartment and IDC-S.
RNA was isolated from the captured cells and interrogated
with the Affymetrix whole-genome array U133X3P.
Gene expression changes in the stromal and epithelial 
compartments during breast cancer progression
We compared the gene expression patterns of the tumor epi-
thelium and stroma at each stage of progression (DCIS or
IDC) with their respective normal state using the limma (linear
models of microarrays) software package [12]. The resulting P
values for differential gene expression in each pair-wise com-
parison were adjusted for multiple testing [13], and the genes
with a significant adjusted P value (P <0.05) were extracted.
The DCIS and IDC stages were each associated with thou-
sands of gene expression alterations relative to their respec-
tive normal state in both the tumor epithelium and the stroma
(Figure 2). Furthermore, within each compartment, the expres-
sion patterns of DCIS-associated and IDC-associated genes
were highly similar to each other (Figure 3).
To gain an overview of the biological processes in which these
differentially expressed genes are involved, we performed
gene set enrichment analysis [19] using the gene ontology
database [20]. Table 3 presents the top 20 gene ontology
terms significantly enriched within genes upregulated in the
invasive stage in the epithelium and the stroma. In the epithe-
lium, the genes were dominated by those associated with the
cell cycle (mitosis in particular). In the stroma, the genes prom-
inently featured the components of the extracellular matrix and
the matrix metalloproteases responsible for remodeling the
extracellular matrix. Additionally, the stromal genes also
included those related to the cell cycle, indicating increased
proliferation as a common feature in both the tumor epithelium
and the stroma.
In both compartments, the single gene ontology term
STRUCTURAL_CONSTITUENT_OF_RIBOSOME was signif-
icantly enriched within the downregulated genes (Table 3). To
examine this further, we extracted all ribosomal protein-encod-
ing genes that were differentially expressed between DCIS or
IDC versus the normal breast in the epithelium and visualized
Table 2
Laser capture microdissection of 14 primary breast cancer 
patients
Tumor Stroma
Patient Normal In situ Invasive Normal In situ Invasive
44 x x x x x x
45 x x x x x
79 x x x x x
96 x x x x x x
102 x x x x x x
121 x x x x x x
1 3 1 xx xx
1 3 3 xx xx
1 4 8 xx xx
1 5 3 xx xx
1 6 9 xx xx
1 7 8 xx xx
1 7 9 xx xx
1 8 0 xx xx
x, component captured.
Figure 2
Comparative analysis of gene expression changes in tumor and stroma Comparative analysis of gene expression changes in tumor and stroma. 
Gene expression changes in normal breast epithelium (N), ductal carci-
noma in situ (DCIS), invasive ductal carcinoma (IDC), normal stromal 
compartment (N-S), ductal carcinoma in situ-associated stroma (DCIS-
S) and invasive ductal carcinoma-associated stroma (IDC-S). ↑, upreg-
ulated genes; ↓, downregulated genes.Available online http://breast-cancer-research.com/content/11/1/R7
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Figure 3
Heatmap of expression patterns of ductal carcinoma in situ-associated and invasive ductal carcinoma-associated genes Heatmap of expression patterns of ductal carcinoma in situ-associated and invasive ductal carcinoma-associated genes. (a) Heatmap of 849 genes 
with >3-fold differential expression in either ductal carcinoma in situ (DCIS) versus normal breast or invasive ductal carcinoma (IDC) versus normal 
breast in the epithelium. (b) Heatmap of 557 genes with >3-fold differential expression in either ductal carcinoma in situ-associated stroma (DCIS-
S) versus normal stromal compartment or invasive ductal carcinoma-associated stroma (IDC-S) versus normal stromal compartment. Data shown are 
log2(fold change) relative to the average expression in normal controls (normal breast epithelium or normal stromal compartment). In each heatmap, 
genes (rows) are hierarchically clustered using 1 – Pearson correlation as the distance metric. IS, ductal carcinoma in situ; INV, invasive ductal car-
cinoma; ISS, ductal carcinoma in situ-associated stroma; INVS, invasive ductal carcinoma-associated stroma.Breast Cancer Research    Vol 11 No 1    Ma et al.
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Table 3
Top 20 gene ontology terms enriched in tumor epithelium and stroma
Name Size (number of genes) Normalized enrichment score False discovery rate q value
Epithelium
SPINDLE 39 2.33 0
CHROMOSOME_SEGREGATION 28 2.15 0
CELL_CYCLE_PROCESS 180 2.12 0
MICROTUBULE_CYTOSKELETON_ORGANIZATION_A
ND_BIOGENESIS
34 2.11 0
CHROMOSOME__PERICENTRIC_REGION 27 2.11 0
MICROTUBULE_CYTOSKELETON 142 2.11 0
PROTEASOME_COMPLEX 22 2.09 1.40 × 10-4
CONDENSED_CHROMOSOME 30 2.06 2.48 × 10-4
M_PHASE 105 2.06 2.20 × 10-4
NUCLEAR_ENVELOPE 71 2.05 1.98 × 10-4
CELL_CYCLE_PHASE 157 2.05 1.80 × 10-4
M_PHASE_OF_MITOTIC_CELL_CYCLE 78 2.04 2.49 × 10-4
CHROMOSOME 115 2.03 2.30 × 10-4
CYTOSKELETAL_PART 221 2.03 2.14 × 10-4
MITOSIS 75 2.02 2.66 × 10-4
MICROTUBULE 32 1.99 2.49 × 10-4
MITOTIC_CELL_CYCLE 139 1.99 2.35 × 10-4
CELL_CYCLE_CHECKPOINT_GO_0000075 45 1.98 2.21 × 10-4
SPINDLE_MICROTUBULE 16 1.97 2.63 × 10-4
DNA_REPAIR 120 1.94 6.01 × 10-4
STRUCTURAL_CONSTITUENT_OF_RIBOSOME 74 -3.09 0
Stroma
EXTRACELLULAR_MATRIX_STRUCTURAL_CONSTITU
ENT
25 2.12 0
COLLAGEN 23 2.07 0.001566
METALLOENDOPEPTIDASE_ACTIVITY 26 2.06 0.001044
EXTRACELLULAR_MATRIX 94 1.99 0.001568
PROTEINACEOUS_EXTRACELLULAR_MATRIX 93 1.97 0.002923
EXTRACELLULAR_MATRIX_PART 54 1.91 0.007826
SPINDLE 39 1.89 0.008346
METALLOPEPTIDASE_ACTIVITY 45 1.82 0.027006
SKELETAL_DEVELOPMENT 99 1.80 0.032482
STRUCTURAL_CONSTITUENT_OF_RIBOSOME 74 -3.04 0Available online http://breast-cancer-research.com/content/11/1/R7
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Figure 4
Heatmap of differential expression of ribosomal protein genes in the malignant epithelium and tumor stroma Heatmap of differential expression of ribosomal protein genes in the malignant epithelium and tumor stroma. Differential expression of ribosomal pro-
tein genes in ductal carcinoma in situ (DCIS), invasive ductal carcinoma (IDC), ductal carcinoma in situ-associated stroma (DCIS-S) and invasive 
ductal carcinoma-associated stroma (IDC-S). Data shown are log2(fold change) relative to the average expression level in the normal controls (nor-
mal breast epithelium or normal stromal compartment). Expression measurements for multiple probe sets representing the same gene were col-
lapsed to the single representative probe set with the largest differential gene expression. All genes shown were significant at adjusted P < 0.05. IS, 
ductal carcinoma in situ; INV, invasive ductal carcinoma; ISS, ductal carcinoma in situ-associated stroma; INVS, invasive ductal carcinoma-associ-
ated stroma.Breast Cancer Research    Vol 11 No 1    Ma et al.
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Table 4
Top 50 genes differentially expressed in tumor epithelium
Probe set DICS IDC Gene description
g5174662_3p_at 5.3 4.0 S100P – S100 calcium binding protein P
g11993936_3p_s_at 4.5 3.4 CYB561 – cytochrome b-561
g7415720_3p_a_at 4.0 3.0 SCD – stearoyl-CoA desaturase (delta-9-desaturase)
Hs.75319.0.S3_3p_at 3.0 3.8 RRM2 – ribonucleotide reductase M2 polypeptide
Hs.106552.0.S3_3p_s_at 4.2 2.3 CNTNAP2 – contactin associated protein-like 2
g12803628_3p_at 3.7 2.6 HIST1H1C – histone cluster 1, H1c
g5031780_3p_at 4.0 2.3 IFI27 – interferon, alpha-inducible protein 27
Hs.180779.1.S1_3p_at 3.1 3.0 HIST1H2BD – histone cluster 1, H2bd
Hs.184572.0.S2_3p_at 2.7 3.3 CDC2 – cell division cycle 2, G1 to S and G2 to M
Hs.223025.0.S2_3p_a_at 2.6 3.4 RAB31 – RAB31, member RAS oncogene family
g12804874_3p_a_at 2.8 3.1 RRM2 – ribonucleotide reductase M2 polypeptide
Hs.239884.0.S1_3p_x_at 3.5 2.4 HIST1H2BC – histone cluster 1, H2bc
g7661973_3p_at 2.7 3.1 MELK – maternal embryonic leucine zipper kinase
g13259549_3p_at 3.2 2.4 IFI6 – interferon, alpha-inducible protein 6
g4504584_3p_at 3.5 2.0 IFIT1 – interferon-induced protein with tetratricopeptide repeats 1
Hs.155956.0.S1_3p_at 2.6 2.8 NAT1 – N-acetyltransferase 1 (arylamine N-acetyltransferase)
Hs.152677.0.S1_3p_at 3.1 2.3 DHRS2 – dehydrogenase/reductase (SDR family) member 2
Hs.239884.0.S1_3p_at 3.3 2.1 HIST1H2BC – histone cluster 1, H2bc
g5803130_3p_a_at 2.2 3.2 RAB31 – RAB31, member RAS oncogene family
g13699814_3p_s_at 2.7 2.7 CYP2B6 – cytochrome P450, family 2, subfamily B, polypeptide 6
g9963780_3p_a_at 2.2 3.2 RAB31 – RAB31, member RAS oncogene family
Hs.72472.0.A1_3p_at 2.3 2.9 -
g13477106_3p_s_at 3.3 1.8 CEACAM6 – carcinoembryonic antigen-related cell adhesion molecule 6 
(nonspecific cross-reacting antigen)
Hs.133342.0.S1_3p_x_at 2.9 2.2 GPC1 – glypican 1
Hs.325335.1.S1_3p_at 2.6 2.5 CAPN13 – calpain 13
Hs.34853.0.S2_3p_at -3.5 -4.0 ID4 – inhibitor of DNA binding 4, dominant negative helix-loop-helix protein
g3387766_3p_a_at -3.9 -3.6 GPM6B – glycoprotein M6B
Hs.10587.0.S1_3p_at -3.2 -4.3 DMN – desmuslin
Hs2.348883.1.S1_3p_s_at -3.9 -3.6 FOXC1 – forkhead box C1
g4758521_3p_at -4.9 -2.7 SPARCL1 – SPARC-like 1 (mast9, hevin)
g11037715_3p_x_at -3.9 -3.7 ROPN1 – ropporin, rhophilin associated protein 1
g4504914_3p_at -3.9 -3.8 KRT15 – keratin 15
Hs.82101.0.S3_3p_at -3.7 -4.0 PHLDA1 – pleckstrin homology-like domain, family A, member 1
Hs.149356.0.S1_3p_at -3.8 -3.9 LOC728264 – hypothetical protein LOC728264
g4506856_3p_s_at -3.3 -4.6 CX3CL1 – chemokine (C-X3-C motif) ligand 1
g4506516_3p_at -3.9 -4.1 RGS2 – regulator of G-protein signaling 2, 24 kDa
g7657105_3p_at -4.2 -4.0 GABRP – gamma-aminobutyric acid (GABA) A receptor, pi
Hs.25956.0.S1_3p_at -4.1 -4.4 SOSTDC1 – sclerostin domain containing 1Available online http://breast-cancer-research.com/content/11/1/R7
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their expression patterns in both compartments. Interestingly,
there was an almost complete bipartite partitioning of these
genes (Figure 4): while the downregulated genes were all
those encoding for the cytoplasmic ribosomal proteins, the
upregulated genes were mostly those encoding for the mito-
chondrial ribosomal proteins.
In addition to these global patterns, Tables 4 and 5 present the
top 50 differentially expressed genes in the epithelium and the
stroma, respectively. In these tables, besides the dominant
features of cell-cycle-related genes in the epithelium and extra-
cellular matrix genes in the stroma discussed earlier, we note
several additional genes important in cell signaling pathways.
Two antagonists of WNT receptor signaling, WIF1 and
secreted frizzled-related protein 1 (SFRP1), were downregu-
lated in both the tumor epithelium and the stroma. In addition,
two members of the transforming growth factor beta super-
family, GREM1 and inhibin beta A (INHBA), showed markedly
increased expression specifically in the tumor stroma (Table
5).
Stromal gene expression signature associated with 
tumor invasion
We next compared the gene expression patterns associated
with the DCIS to IDC transition within each compartment. In
the tumor epithelium, there were only three genes (POSTN,
periostin; SPARC, osteoconectin; SPARCL1, SPARC-like 1)
that were significantly upregulated in IDC relative to DCIS. All
three genes are known to be specifically expressed in the
stroma [21-23] and were indeed strongly expressed in the
stroma samples in our dataset. Their apparent overexpression
in IDC relative to DCIS might therefore be due to contaminat-
ing stromal cells in the procured epithelial cell populations in
the IDC samples but not in DCIS samples. In the stroma, how-
ever, there were more significant changes in comparing IDC-
S with DCIS-S, with 76 upregulated genes and 229 downreg-
ulated genes (Figure 2). The lack of significant changes in
gene expression in the epithelium associated with the DCIS-
IDC transition seen here was consistent with that in our previ-
ous study [9].
Table 6 presents the top 50 differentially expressed genes
between DICS-S and IDC-S (see Additional data file 1).
Among genes with increased expression in IDC-S, three matrix
metalloproteases (MMP11, MMP2 and MMP14) were nota-
ble. In fact, one additional matrix metalloprotease (MMP13)
had higher expression in IDC-S than in DCIS-S, with adjusted
P = 0.06. These genes have been known to be involved in
tumor invasion [3]. On the other hand, genes with decreased
expression in IDC-S included many genes involved in vascula-
ture development (for example, EMCN, FLT1, KDR, SELE,
MYH11, EDNRB and PODXL), a process expected to
increase in invasive cancer. This paradoxical result might
reflect the decreased vascular density in the leading invasive
front where we microdissected the stroma relative to the
stroma surrounding DCIS.
Stromal gene expression signature associated with 
tumor grade
We have previously shown that tumor grade is associated with
a strong gene expression signature in malignant breast epithe-
lial cells [9]. We therefore examined whether a similar signa-
ture also exists in the tumor stroma. Comparing grade I (n = 8)
and grade III (n = 7) tumor-associated stroma samples (DCIS-
S and IDC-S), we identified 526 upregulated genes and 94
downregulated genes in grade III samples (Figure 5; see also
Additional data file 2). The gene set enrichment analysis indi-
cated that the tumor stroma in grade III tumors were associ-
ated with a strong immune response signature (interferon
Hs.153961.2.S2_3p_at -4.6 -3.9 BOC – Boc homolog (mouse)
g11991655_3p_at -4.5 -4.2 C2orf40 – chromosome 2 open reading frame 40
Hs.288850.0.S1_3p_at -4.1 -4.7 PHLDA1 – pleckstrin homology-like domain, family A, member 1
g7662650_3p_at -5.1 -3.7 C13orf15 – chromosome 13 open reading frame 15
g4557694_3p_a_at -4.5 -4.5 KIT – v-kit Hardy-Zuckerman 4 feline sarcoma viral oncogene homolog
Hs.127428.2.S2_3p_a_at -4.3 -4.9 HOXA9 – homeobox A9
g6005949_3p_at -4.4 -4.8 WIF1 – WNT inhibitory factor 1
Hs.34853.0.S3_3p_at -4.8 -4.5 ID4 – inhibitor of DNA binding 4, dominant negative helix-loop-helix protein
g4559274_3p_a_at -4.1 -5.3 ELF5 – E74-like factor 5 (ets domain transcription factor)
g8400731_3p_a_at -4.4 -5.2 SFRP1 – secreted frizzled-related protein 1
g5032314_3p_a_at -4.9 -4.9 DMD – dystrophin (muscular dystrophy, Duchenne and Becker types)
g6005714_3p_at -4.7 -5.6 SLC6A14 – solute carrier family 6 (amino acid transporter), member 14
Ductal carcinoma in situ (DCIS) and invasive ductal carcinoma (IDC) data presented as log2(fold changes) relative to normal epithelium.
Table 4 (Continued)
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Table 5
Top 50 genes differentially expressed in tumor-associated stroma
Probe set DCIS IDC Gene description
Hs.179729.0.S1_3p_a_at 6.5 7.0 COL10A1 – collagen, type X, alpha 1(Schmid metaphyseal chondrodysplasia)
Hs.28792.0.S1_3p_at 5.9 6.0 NA
4876385_3p_at 4.9 6.3 COL11A1 – collagen, type XI, alpha 1
g7019348_3p_at 4.9 5.7 GREM1 – gremlin 1, cysteine knot superfamily, homolog (Xenopus laevis)
Hs.179729.1.S1_3p_a_at 4.8 5.5 COL10A1 – collagen, type X, alpha 1(Schmid metaphyseal chondrodysplasia)
Hs.297939.3.S1_3p_at 4.6 5.1 FNDC1 – fibronectin type III domain containing 1
37892_3p_at 4.1 5.6 COL11A1 – collagen, type XI, alpha 1
Hs.41271.0.S1_3p_at 4.7 4.9 COL8A1 – collagen, type VIII, alpha 1
g4502938_3p_s_at 3.8 5.4 COL11A1 – collagen, type XI, alpha 1
g186414_3p_a_at 4.5 4.4 INHBA – inhibin, beta A
g8393842_3p_at 4.4 4.4 NOX4 – NADPH oxidase 4
Hs.288467.0.S1_3p_at 3.8 4.8 LRRC15 – leucine rich repeat containing 15
Hs.105700.0.S1_3p_a_at 4.1 4.2 SFRP4 – secreted frizzled-related protein 4
g4481752_3p_at 3.6 4.4 GJB2 – gap junction protein, beta 2, 26 kDa
g8923132_3p_at 3.6 4.3 ASPN – asporin
Hs.287820.2.A1_3p_s_at 3.8 4.1 FN1 – fibronectin 1
g8400733_3p_a_at 3.5 3.9 SFRP4 – secreted frizzled-related protein 4
g10863087_3p_a_at 3.4 3.9 GREM1 – gremlin 1, cysteine knot superfamily, homolog (Xenopus laevis)
g5174662_3p_at 3.4 3.4 S100P – S100 calcium binding protein P
Hs.283713.0.A1_3p_at 3.2 3.5 CTHRC1 – collagen triple helix repeat containing 1
g4502844_3p_at 3.1 3.5 CILP – cartilage intermediate layer protein, nucleotide pyrophosphohydrolase
Hs.76722.2.S1_3p_at 2.8 3.7 -
Hs.70823.0.S3_3p_at 3.3 3.2 SULF1 – sulfatase 1
g4505186_3p_at 3.3 3.0 CXCL9 – chemokine (C-X-C motif) ligand 9
Hs.101302.0.S2_3p_s_at 2.2 3.9 COL12A1 – collagen, type XII, alpha 1
g11415037_3p_at -3.2 -3.0 SLC22A3 – solute carrier family 22 (extraneuronal monoamine transporter), member 3
Hs.325823.0.A1_3p_at -2.7 -3.5 CD36 – CD36 molecule (thrombospondin receptor)
g4557418_3p_at -2.7 -3.6 CD36 – CD36 molecule (thrombospondin receptor)
g4557544_3p_a_at -2.9 -3.5 EDN3 – endothelin 3
Hs2.147313.1.S1_3p_s_at -2.9 -3.5 CD300LG – CD300 molecule-like family member g
Hs.106283.4.S1_3p_at -3.0 -3.4 KLHL13 – kelch-like 13 (Drosophila)
g8400731_3p_a_at -2.6 -4.0 SFRP1 – secreted frizzled-related protein 1
Hs.250692.0.S4_3p_at -3.0 -3.7 HLF – hepatic leukemia factor
g4826977_3p_at -3.3 -3.5 RELN – reelin
Hs.76325.1.A1_3p_x_at -3.0 -3.9 IGJ – immunoglobulin J polypeptide, linker protein for immunoglobulin alpha and mu polypeptides
Hs.76325.1.A1_3p_at -3.1 -4.0 IGJ – immunoglobulin J polypeptide, linker protein for immunoglobulin alpha and mu polypeptides
g10835124_3p_a_at -4.0 -3.1 DCX – doublecortex; lissencephaly, X-linked (doublecortin)
g7657105_3p_at -3.2 -4.0 GABRP – gamma-aminobutyric acid A receptor, pi
g4506328_3p_at -3.4 -3.9 PTPRZ1 – protein tyrosine phosphatase, receptor-type, Z polypeptide 1Available online http://breast-cancer-research.com/content/11/1/R7
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signaling, activation of leukocytes and T cells) and with
increased mitotic activity (Table 7).
Validation of selected differentially expressed genes
We next used quantitative real-time PCR to validate selected
genes differentially expressed in the various comparisons pre-
sented above. Quantitative real-time PCR analysis of the same
samples as used in the microarray analysis confirmed the
marked downregulation of WIF1 in both neoplastic epithelium
and tumor stroma (Figure 6a) and the marked upregulation of
GREM1 in both DCIS-associated and IDC-associated stroma
(Figure 6b). In addition, two representative genes (ESR1,
estrogen receptor alpha; and RRM2, ribonucleotide reductase
M2 subunit) differentially expressed in the stroma between
grade III and grade I tumors (see Additional data file 2) were
also confirmed by quantitative real-time PCR. In both the epi-
thelium and stroma, RRM2, a cell proliferation marker, was
more highly expressed in grade III tumors (Figure 6c), whereas
ESR1 was more highly expressed in grade I tumors (Figure
6d). Although expression of estrogen receptor alpha is
thought to be restricted to the tumor epithelial cells in human
breast cancer [24], we confirmed the low but detectable levels
of estrogen receptor alpha expression in stromal fibroblasts by
immunohistochemical staining (Figure 6e).
Discussion
Exploratory genome-wide analysis of the tumor microenviron-
ment in breast cancer has been limited to date. Using serial
analysis of gene expression coupled with antibody-based ex
vivo tissue fractionation, Allinen and colleagues identified a
limited set of 417 cell-type-specific genes among the most
prominent cell types in breast cancer (epithelial, myoepithelial,
and endothelial cells, fibroblasts, and leukocytes) [7]. Finak
and colleagues more recently obtained gene expression pro-
files of both epithelial and stromal compartments from the
same tumor biopsy via LCM [25]. These workers only analyzed
the morphologically normal epithelium and normal stroma,
however, leaving the gene expression changes in the tumor-
activated stroma unexplored. Our work therefore provides the
first comprehensive comparative analysis of in vivo gene
expression changes in the tumor epithelium and its stromal
microenvironment during breast cancer progression from nor-
mal to DCIS to IDC.
We observed extensive gene expression changes in the
stroma associated with DCIS and IDC, suggesting that tumor-
adjacent stroma coevolves with the tumor epithelium, even
before tumor invasion occurs. These alterations included many
components of the extracellular matrix and the extracellular-
matrix-remodeling matrix metalloproteases. Increased mitotic
gene expression occurred both in the malignant epithelium
and adjacent stroma, which may reflect the often observed
desmoplastic reaction around the tumor cells. Expression of
cytoplasmic ribosomal proteins was generally decreased in
both compartments during cancer progression. While this
result may seem paradoxical in that increased protein synthe-
sis is considered a hallmark of cancer, it is supported by sev-
eral different lines of studies. First, decreased expression of
many ribosomal proteins has also been observed in colorectal
cancer compared with normal mucosal epithelium [26]. Sec-
ondly, many ribosomal protein genes have been found to be
haploinsufficient tumor suppressors in zebrafish [27]. Thirdly,
the oncogenic activity of c-Myc is inhibited by the ribosomal
protein L11, and inactivation of the L11 gene by small interfer-
ing RNA increases c-Myc-induced transcription and cell prolif-
eration [28].
The mechanism by which ribosomal proteins contribute to
tumorigenesis is unknown. Decreased expression of ribos-
omal proteins in cancer may reflect a qualitative change in
ribosomal structure, which may allow differential translation of
gene products required for rapid tumor growth. Alternatively, it
g4758377_3p_at -3.9 -3.4 FIGF – c-fos induced growth factor (vascular endothelial growth factor D)
g12707575_3p_at -3.3 -4.1 OXTR – oxytocin receptor
g13518036_3p_a_at -2.5 -4.9 MATN2 – matrilin 2
g4559274_3p_a_at -3.9 -3.6 ELF5 – E74-like factor 5 (ets domain transcription factor)
Hs.10587.0.S1_3p_at -2.5 -5.1 DMN – desmuslin
Hs.49696.0.A1_3p_at -3.7 -4.0 SCARA5 – scavenger receptor class A, member 5 (putative)
g4557578_3p_at -3.4 -4.4 FABP4 – fatty acid binding protein 4, adipocyte
g13186315_3p_a_at -3.5 -4.3 CAPN6 – calpain 6
g11991655_3p_at -3.2 -5.3 C2orf40 – chromosome 2 open reading frame 40
g562105_3p_a_at -4.9 -4.5 DLK1 – delta-like 1 homolog (Drosophila)
g6005949_3p_at -5.0 -4.8 WIF1 – WNT inhibitory factor 1
Ductal carcinoma in situ (DCIS) and invasive ductal carcinoma (IDC) data presented as log2(fold changes) relative to normal stroma.
Table 5 (Continued)
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Table 6
Top 50 genes differentially expressed in invasive stroma compared to in situ stroma
Probe set Log2 (fold change) Adjusted P value Gene description
Hs2.434299.1.S1_3p_at 1.61 8.58 × 10-3 -
g13027795_3p_s_at 1.45 1.74 × 10-2 MMP11 – matrix metallopeptidase 11 (stromelysin 3)
Hs.50081.1.S1_3p_a_at 1.36 5.47 × 10-3 KIAA1199 – KIAA1199
g11641276_3p_s_at 1.24 3.71 × 10-2 PDE4DIP – phosphodiesterase 4D interacting protein (myomegalin)
Hs.169517.0.S1_3p_a_at 1.16 5.72 × 10-3 ALDH1B1 – aldehyde dehydrogenase 1 family, member B1
Hs.98523.0.A1_3p_at 1.13 5.32 × 10-3 FAT3 – FAT tumor suppressor homolog 3 (Drosophila)
g10938018_3p_at 1.04 1.74 × 10-2 EPYC – epiphycan
Hs2.350890.1.S1_3p_s_at 1.03 3.72 × 10-2 GABRB2 – gamma-aminobutyric acid (GABA) A receptor, beta 2
g4507922_3p_at 0.98 1.70 × 10-2 WISP2 – WNT1 inducible signaling pathway protein 2
g11342665_3p_at 0.98 4.53 × 10-2 MMP2 – matrix metallopeptidase 2 
(gelatinase A, 72kDa gelatinase, 72 kDa type IV collagenase)
g13124890_3p_a_at 0.93 3.28 × 10-2 GALNT1 – UDP-N-acetyl-alpha-D-galactosamine:polypeptide N-
acetylgalactosaminyltransferase 1 (GalNAc-T1)
Hs.98523.0.A1_3p_x_at 0.87 3.15 × 10-2 FAT3 – FAT tumor suppressor homolog 3 (Drosophila)
Hs.238532.0.A1_3p_at 0.76 3.71 × 10-2 GALNTL2 – UDP-N-acetyl-alpha-D-galactosamine:polypeptide N-
acetylgalactosaminyltransferase-like 2
Hs.42927.0.S1_3p_at 0.75 3.39 × 10-2 ANTXR1 – anthrax toxin receptor 1
Hs2.359399.1.S1_3p_at 0.74 3.71 × 10-2 LOC285758 – hypothetical protein LOC285758
Hs.235795.0.A1_3p_at 0.74 1.38 × 10-2 -
Hs2.46679.2.S1_3p_s_at 0.66 2.11 × 10-3 -
g469044_3p_a_at 0.60 3.22 × 10-2 CNTN1 – contactin 1
g4758607_3p_at 0.53 1.20 × 10-2 -
Hs.288553.0.S1_3p_s_at 0.52 2.82 × 10-2 -
200661_3p_at 0.51 4.16 × 10-2 CTSA – cathepsin A
Hs.2399.1.S1_3p_s_at 0.51 4.48 × 10-2 MMP14 – matrix metallopeptidase 14 (membrane-inserted)
Hs.98183.0.A1_3p_at 0.48 8.58 × 10-3 RSPO4 – R-spondin family, member 4
208756_3p_at 0.48 2.28 × 10-2 EIF3I – eukaryotic translation initiation factor 3, subunit I
Hs.162647.0.S1_3p_at 0.48 2.69 × 10-2 DKFZP547L112 – hypothetical protein DKFZp547L112
Hs.22968.0.S1_3p_a_at -2.00 8.37 × 10-6 FLT1 – fms-related tyrosine kinase 1 
(vascular endothelial growth factor/vascular permeability factor receptor)
g11545907_3p_at -2.03 2.68 × 10-5 ELTD1 – EGF, latrophilin and seven transmembrane domain containing 1
g5032094_3p_at -2.03 3.64 × 10-7 SLCO2A1 – solute carrier organic anion transporter family, member 2A1
Hs.8707.0.S1_3p_at -2.07 1.29 × 10-5 HECW2 – HECT, C2 and WW domain containing E3 ubiquitin protein 
ligase 2
Hs.134970.0.S1_3p_a_at -2.07 6.66 × 10-3 KIF26A – kinesin family member 26A
Hs2.420404.1.S1_3p_at -2.08 7.70 × 10-6 PELO – pelota homolog (Drosophila)
g4504850_3p_a_at -2.11 3.62 × 10-2 KCNK5 – potassium channel, subfamily K, member 5
Hs.288681.0.S1_3p_at -2.13 4.98 × 10-4 THSD7A – thrombospondin, type I, domain containing 7A
g4557546_3p_at -2.15 1.58 × 10-3 EDNRB – endothelin receptor type B
g11321596_3p_at -2.19 1.64 × 10-3 KDR – kinase insert domain receptor (a type III receptor tyrosine kinase)
Hs.124675.0.A1_3p_at -2.21 2.21 × 10-4 GIMAP7 – GTPase, IMAP family member 7Available online http://breast-cancer-research.com/content/11/1/R7
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may reflect some unknown nonribosomal functions by these
proteins. In contrast to the decreased expression of these
cytoplasmic ribosomal protein genes, we observed increased
expression of a number of mitochondrial ribosomal protein
genes in both the tumor epithelium and the stroma. The human
mitochondrial ribosomes are responsible for the production of
several key proteins in bioenergetics including subunits of the
ATP synthase. Given the importance of mitochondria in cancer
[29,30], our novel finding suggests that the mitochondrial
ribosome may be a potential therapeutic target and thus war-
rants further study.
The top differentially expressed genes between tumor-associ-
ated stroma and the adjacent normal stroma included several
signaling molecules known to be important for tumorigenesis.
Two antagonists of WNT receptor signaling, WIF1 and
SFRP1, were consistently downregulated both in the tumor
epithelium and stroma. The WNT signaling pathway plays an
important role in development and tissue homeostasis, and its
aberrant activation by loss of expression WIF1 or SFRP1 has
been shown to be an important early event in breast cancer
progression [31-33]. Two transforming growth factor beta
superfamily members (GREM1 and INHBA) are strongly
induced in the tumor-associated stroma. GREM1 is a bone
morphogenetic protein antagonist, and it is overexpressed in
cancer-associated stromal cells in many solid tumors [34]. It
has been hypothesized that bone morphogenetic proteins and
bone morphogenetic protein antagonists may play opposing
roles in the maintenance of a niche of self-renewing stem cells,
with bone morphogenetic protein antagonists such as
GREM1 blocking cell differentiation [34]. WNT3A was
recently demonstrated in human fibroblasts to markedly
increase the expression of GREM2, a close paralog of
GREM1 – raising the possibility that the significant downreg-
ulation of WNT antagonists (WIF1 and SFRP1) and upregula-
tion of GREM1 in the stroma [35] we observed here may be
functionally linked.
INHBA is the gene for the beta A subunit of inhibin and activin,
which are pleiotropic growth factors regulating the growth and
differentiation of many cell types via autocrine and paracrine
mechanisms [36]. Although its role in breast cancer remains
unclear, circulating levels of INHBA has been shown to be
higher in breast cancer patients with bone metastasis [37].
These signaling molecules could serve as key messengers
between the tumor and its microenvironment, as shown for
CXCL12 and CXCL14, which are overexpressed in tumor-
associated myoepithelial cells and myofibroblasts [6,7,38].
We note that in our dataset, however, CXCL12 and CXCL14
were also expressed in normal stroma. This discrepancy could
be due to the fact that Allinen and colleagues used purified
stromal cell types [7] and we used the whole stroma compart-
ment in our study.
A watershed event in breast cancer progression is the invasion
of tumor cells into the stromal compartment. The only morpho-
logical diagnostic criterion distinguishing DCIS from IDC is
the association of DCIS with a complete basement membrane.
Understanding the molecular events that drive the DCIS-IDC
transition has been of great interest. We have previously
shown [9], and confirm in the present study, that the malignant
epithelium of DCIS and IDC are very similar without significant
differences at the transcriptome level. This conclusion is sup-
ported by the recent demonstration that MCFDCIS cells, a cell
Hs.211388.0.S1_3p_at -2.24 5.72 × 10-3 RUNDC3B – RUN domain containing 3B
g4885556_3p_at -2.25 2.13 × 10-3 PODXL – podocalyxin-like
Hs.26530.0.S2_3p_at -2.30 1.60 × 10-3 SDPR – serum deprivation response (phosphatidylserine binding protein)
g13518036_3p_a_at -2.41 7.19 × 10-3 MATN2 – matrilin 2
Hs.102415.0.S1_3p_at -2.43 2.67 × 10-8 EMCN – endomucin
Hs.61935.0.S1_3p_at -2.45 2.68 × 10-5 PCDH17 – protocadherin 17
g8547214_3p_at -2.46 3.74 × 10-5 EMCN – endomucin
g4520327_3p_at -2.48 2.67 × 10-3 IL33 – interleukin 33
Hs.10587.0.S1_3p_at -2.66 2.29 × 10-3 DMN – desmuslin
g3644039_3p_a_at -2.67 1.43 × 10-2 TP63 – tumor protein p63
Hs.78344.1.S2_3p_a_at -2.87 2.13 × 10-3 MYH11 – myosin, heavy chain 11, smooth muscle
g6580814_3p_s_at -2.93 8.90 × 10-5 INMT – indolethylamine N-methyltransferase
Hs.173560.0.S1_3p_at -2.94 3.58 × 10-2 ODZ2 – odz, odd Oz/ten-m homolog 2 (Drosophila)
g4506870_3p_at -3.23 1.80 × 10-3 SELE – selectin E (endothelial adhesion molecule 1)
Table 6 (Continued)
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line model for DCIS, make the DCIS-IDC transition spontane-
ously without further molecular changes in the malignant epi-
thelial cells themselves [39]. Instead, this transition is driven by
fibroblasts and blocked by myoepithelial cells.
In the present article we demonstrated that the stromal com-
partment is associated with a relatively small number of signif-
icant changes accompanying the DCIS-IDC transition. In
particular, several matrix metalloproteases (MMP2, MMP11
and MMP14) showed significantly increased expression in
IDC-associated stroma. MMP14, a membrane-type matrix
metalloprotease, can activate MMP2 protease activity, which
degrades type IV collagen, the major structural component of
the basement membrane [40,41]. MMP11 has recently been
shown to exhibit protease activity towards type VI collagen
and to promote tumor progression [42]. MMP11 has been
shown to be differentially expressed in IDC relative to DCIS in
two other studies. Schuetz and colleagues conducted a study
similar to ours, using LCM and microarrays to profile the epi-
thelium of patient-matched DCIS and IDC, and found MMP11
to be upregulated in IDC relative to DCIS [43]. Their result dif-
fers from ours, however, in that we observed upregulation of
MMP11 in the IDC-associated stroma but not in the epithe-
lium. A stromal origin of MMP11 expression had been estab-
lished previously [44]. The result by Schuetz and coworkers
might be due to contaminating nonepithelial cells in their LCM
samples, a possibility acknowledged by these authors [43]. In
another study, Hannemann and colleagues identified a gene
expression signature including MMP11 to be able to distin-
guish IDC from DCIS [45]. Since no microdissection was per-
formed in that study, the gene expression profiles they
obtained were from mixtures of tumor epithelium and stroma.
Nevertheless, our results together with these other studies
support the notion that stroma-produced matrix metallopro-
teases may be key players driving the DCIS-IDC transition.
Finally, we showed that – like the epithelial compartment [9] –
tumor stroma also exhibited a robust gene expression signa-
ture correlating with the histological tumor grade. These genes
are primarily involved in immune response and cell-cycle pro-
gression. The association of an immune response signature
with the more aggressive high-grade tumors is seemingly par-
Table 7
Top 20 gene sets enriched in grade III-associated stroma
Name Size (number of genes) Normalized enrichment score False discovery rate q value
CELLULAR_DEFENSE_RESPONSE 52 2.31 0
IMMUNE_RESPONSE 220 2.17 0
IMMUNE_SYSTEM_PROCESS 312 2.16 0
T_CELL_ACTIVATION 42 2.14 0
LEUKOCYTE_ACTIVATION 67 2.09 0
JAK_STAT_CASCADE 28 2.05 6.82 × 10-4
LYMPHOCYTE_ACTIVATION 59 2.05 5.85 × 10-4
CELL_ACTIVATION 73 2.04 5.12 × 10-4
M_PHASE_OF_MITOTIC_CELL_CYCLE 78 2.04 4.55 × 10-4
RESPONSE_TO_VIRUS 48 2.04 5.12 × 10-4
SPINDLE 39 2.03 5.60 × 10-4
MITOSIS 75 2.02 5.99 × 10-4
INTERLEUKIN_RECEPTOR_ACTIVITY 20 2.01 6.33 × 10-4
POSITIVE_REGULATION_OF_IMMUNE_RESPONSE 28 2.00 7.35 × 10-4
REGULATION_OF_IMMUNE_SYSTEM_PROCESS 66 1.99 7.54 × 10-4
POSITIVE_REGULATION_OF_IMMUNE_SYSTEM_PRO
CESS
50 1.99 7.07 × 10-4
RESPONSE_TO_BIOTIC_STIMULUS 112 1.99 6.65 × 10-4
REGULATION_OF_I_KAPPAB_KINASE_NF_KAPPAB_
CASCADE
89 1.99 6.85 × 10-4
MRNA_PROCESSING_GO_0006397 67 1.97 0.001135
RESPONSE_TO_OTHER_ORGANISM 76 1.96 0.001282Available online http://breast-cancer-research.com/content/11/1/R7
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adoxical. The interactions between tumor cells and the various
immune cells are complex, however, ranging from tumor
growth-suppressing effects to tumor growth-promoting
effects [46-48]. Perhaps the immune response signature
associated with high-grade tumors represents the escape
phase [48], when the cancer cells become resistant to
immune attack and hijack the abundant cytokines and chem-
okines made by the immune cells to grow, invade and spread
to distant organs.
Figure 5
Heatmap of gene expression signature correlated with tumor grade in the stroma Heatmap of gene expression signature correlated with tumor grade in the stroma. Comparison of grade III tumors with grade I tumors identified 526 
upregulated genes and 94 downregulated genes in grade III stroma. Data shown are log2(fold change) relative to the median expression level across 
all samples. Genes in rows were hierarchically clustered, and samples in columns were arranged by sample type. E, epithelium; S, stroma.Breast Cancer Research    Vol 11 No 1    Ma et al.
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Figure 6
Validation of selected genes Validation of selected genes. (a) to (d) Boxplots of relative gene expression by quantitative real-time PCR in ductal carcinoma in situ (DCIS), inva-
sive ductal carcinoma (IDC), ductal carcinoma in situ-associated stroma (DCIS-S) and invasive ductal carcinoma-associated stroma (IDC-S). (a) and 
(b) Reference groups were the normal components (N, normal breast epithelium; N-S, normal stromal compartment). (c) and (d) Reference groups 
were grade I (EI, epithelium; SI, stroma). y axis, cycling threshold values relative to the median value for the entire series. Statistically significant dif-
ferences by Wilcoxon rank sum test: *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001.(e) Immunostaining of an estrogen-receptor-positive 
breast cancer. Arrows point to positive staining in stromal fibroblasts.Available online http://breast-cancer-research.com/content/11/1/R7
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Conclusions
The present study provides the first comparative analysis of
the in situ gene expression profiles of patient-matched normal
and neoplastic breast epithelial and stromal compartments of
both preinvasive and invasive stages of human breast cancer
progression. This study of the breast cancer microenvironment
at the transcriptome level and previous studies at the genomic
[49,50] and epigenetic [51,52] levels support the view that
the tumor microenvironment is an important co-conspirator
rather than a passive bystander during tumorigenesis. Molec-
ular alterations within the stroma offer novel avenues for ther-
apeutic interventions and disease prognosis [53]. This gene
expression dataset of carefully procured in situ tumor epithe-
lium and stroma should be a timely and valuable addition to the
resources for the breast cancer research community.
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